Company intelligence / Profile preview

Epion Therapeutics

Burlington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Epion's EpiSmart system demonstrated vision improvement, rapid recovery, very low adverse event rates, and the ability to treat both eyes simultaneously in a >2,000-patient Phase 2 trial; two ongoing Phase 3 trials (Apricity A and B) are slated to conclude Q4 2025.

Therapeutic areas: Ophthalmology
Modalities: Small molecule (riboflavin)Device (UVA light therapy device)
Industry: Biotech

Partnerships

AXA IM Alts (healthcare investor, not a pharma partner)Multiple clinical site collaborations in the US

Beyond the preview

Go deeper on Epion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epion Therapeutics.

Explore the full profile